About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Effects of Arzoxifene on Bone Mass and the Uterus

NCT00085956·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Eli Lilly and Company

Age

45–60

Sex

FEMALE

Healthy volunteers

Accepted

You may be eligible if

Female
45 to 60 years of age, inclusive
At least 2 years since last menstrual cycle
Intact uterus (womb).

You may not be if

Existing fracture of the spine.
Bone disorders, other than low bone mass
History of cancer in the last 5 years. Also, any history, at any time, of breast cancer or cancer of the lining of the uterus.
Abnormal or unexplained vaginal bleeding.

The record

StatusCompleted

PhasePhase 3

Taking part300

StartedApr 2004

UpdatedMar 9, 2007

Conditions

Postmenopausal Bone Loss

Where1

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
San Diego, California, United States

Clareo Health | Effects of Arzoxifene on Bone Mass and the Uterus